U.S. Personal Products Stock News

Celcuity (NasdaqCM:CELC) received FDA Priority Review for its New Drug Application for gedatolisib in advanced breast cancer. The Priority Review follows strong Phase 3 efficacy results from the VIKTORIA-1 trial in HR-positive, HER2-negative breast cancer. An additional Phase 3 readout for the PIK3CA mutant cohort is upcoming and could further influence treatment standards for this patient group. Celcuity focuses on targeted therapies for cancer, with gedatolisib as a key asset in its...

Leadership reshuffle puts technology and deal-making in focus Royalty Pharma (RPRX) has refreshed its senior ranks, naming Lucas Glass as Head of Artificial Intelligence and bringing in Greg Butz as Executive Vice President, Partnering & Investments, while also reinforcing its leadership presence in Asia. See our latest analysis for Royalty Pharma. At a share price of US$46.94, Royalty Pharma has posted a 19.68% 90 day share price return and a 51.83% 1 year total shareholder return, as...

If you are wondering whether Centene's current share price offers value or just more volatility, it helps to break the story down into what the market has been pricing in and how that compares with fundamentals. The stock closed at US$33.56, with returns of a 5.7% decline over 7 days, a 20.8% decline over 30 days, a 19.7% decline year to date, a 44.3% decline over the last year, a 47.7% decline over 3 years and a 46.9% decline over 5 years. This history sets a very specific backdrop for any...

Krystal Biotech: Stock Performance Context Krystal Biotech (KRYS) has drawn investor attention after a recent pullback, with the stock showing a 1-day return of a 1.39% decline, a 1-month return of a 5.81% decline, and a 1-year return of 37.57%. See our latest analysis for Krystal Biotech. Recent trading has been choppy, with a 30 day share price return of a 5.81% decline contrasting with a 1 year total shareholder return of 37.56%. This indicates that earlier momentum has cooled in the short...

Hologic (HOLX) sits in focus after recent share performance that includes a return of about 21% over the past year. This has prompted investors to reassess the women’s health specialist at around US$75 per share. See our latest analysis for Hologic. That 21.45% 1 year total shareholder return, compared with a relatively modest 1.52% year to date share price return, suggests earlier momentum has cooled somewhat. The stock is settling around US$75.69 as investors reassess potential risks and...

NextDecade Corporation ( NASDAQ:NEXT ) shareholders (or potential shareholders) will be happy to see that insider...

Todd Combs, former Berkshire Hathaway investment manager and CEO of Geico, has taken on a senior investment leadership role at NYSE:JPM. Combs, known for his work alongside Warren Buffett, is now directly managing investments for Jamie Dimon at JPMorgan Chase. For anyone tracking NYSE:JPM, this move relates to how the bank is approaching long term capital allocation and investment oversight. Large global banks have been sharpening their focus on fee based businesses and asset management,...

Public Health Advocacy Institute has filed a landmark product liability lawsuit naming DraftKings as a primary defendant, alleging its online betting platform is designed to encourage compulsive gambling. The complaint targets microbetting features, personalized promotions, and AI driven engagement tools as addictive product elements rather than just marketing choices. FanDuel, Genius Sports, and the NFL are also named, bringing league partnerships and data providers directly into the legal...

AM Best affirmed the credit ratings and outlook for OneMain Holdings’ insurance subsidiaries, reinforcing its view of their financial strength. The decision reflects AM Best’s current assessment of the subsidiaries’ balance sheet quality, risk management and operating performance. For investors watching OneMain Holdings (NYSE:OMF), this rating affirmation comes alongside a mixed share price record. The stock closed at $53.05, with a 4.0% gain over the past week offsetting a 3.9% decline...

If you are wondering whether Lamb Weston Holdings' current share price reflects its underlying value, this article walks through the key signals you can use to judge that for yourself. The stock most recently closed at US$40.83, with returns of 0.5% over 7 days, a 14.9% decline over 30 days, a 3.5% decline year to date and a 22.1% decline over 1 year, alongside a 57.8% decline over 3 years and a 42.9% decline over 5 years. These moves have kept Lamb Weston on the radar for investors looking...

Comstock Resources announced that its Western Haynesville operations in Texas were selected in March 2026 to host the Texas Natural Gas-Fired Power Generation Hub, a U.S.-Japan joint project to be built and operated by NextEra Energy under Japan’s very large US$550 billion investment commitment. This collaboration positions Comstock near the center of a major new demand source for Western Haynesville gas, potentially reshaping its role in U.S. energy infrastructure. We’ll now examine how...

BankUnited’s board has approved a quarterly cash dividend of US$0.33 per common share, a 6% increase from US$0.31, payable on April 30, 2026, to shareholders of record on April 10, 2026. This dividend increase, following a quarter in which BankUnited’s revenue and net interest income exceeded analyst expectations, highlights management’s confidence in the bank’s financial position and its emphasis on cash returns to shareholders. We’ll now examine how the stronger quarter and higher dividend...

Clinical data spotlight raises questions for BioNTech (NasdaqGS:BNTX) investors BioNTech (NasdaqGS:BNTX) has put its oncology ambitions in focus after presenting fresh lung cancer data at the European Lung Cancer Congress in Copenhagen, covering late stage immunomodulators and antibody drug conjugates. See our latest analysis for BioNTech. Despite the positive lung cancer updates and a series of conference appearances in March, BioNTech’s recent momentum has been weak, with a 1 month share...

Backlog-driven interest in MasTec MasTec (MTZ) is drawing investor attention after reporting a record 18 month backlog of US$19b spanning communications, pipeline infrastructure, clean energy and power delivery, along with guidance for revenue and adjusted EBITDA growth in 2026. See our latest analysis for MasTec. Despite a 5.2% 1 day share price decline to US$306.74, MasTec’s momentum has been strong, with a 36.69% 90 day share price return and a very large 1 year total shareholder return of...

CoreWeave (NasdaqGS:CRWV) has secured Zonos as a major client for its AI cloud infrastructure. Zonos plans to use CoreWeave to power real-time compliance, duty, tax, and international checkout services for global commerce. The partnership underscores demand for low latency, scalable AI infrastructure in cross border e-commerce workflows. For investors tracking CoreWeave at a share price of $80.45, this agreement with Zonos adds another real world workload to its AI cloud footprint. The...

If you are wondering whether Collegium Pharmaceutical's current share price reflects its real worth, this breakdown will help you see what the numbers are actually saying about value. The stock closed at US$33.42, with returns of 13.1% over 1 year and 37.1% over 3 years, but a 26.0% decline over 30 days and 26.6% decline year to date may have changed how investors think about its risk and reward profile. Recent coverage has focused on Collegium Pharmaceutical in the context of its share...

Wondering if Mastercard at around US$500 a share is still a quality name at a fair price, or if you would be overpaying for growth that may already be reflected in the stock. The share price closed at US$500.75, with a 2.0% return over the last 7 days, 0.6% over the last 30 days, a year-to-date return of an 11.1% decline, a 9.7% decline over 1 year, and a 41.8% return over both 3 and 5 years. These mixed returns can reflect shifting views on growth potential and risk, with some investors...

PureCycle Technologies recently signed a €40 million Innovation Fund grant agreement with the EU’s CINEA to build its ‘ASTRA PP’ polypropylene dissolution recycling facility in Belgium’s Port of Antwerp-Bruges, targeting annual production of 59,000 tonnes of PureFive resin and supporting EU circularity and decarbonization goals. The project is intended to help European customers meet recycled content rules in packaging and end-of-life vehicles, positioning PureCycle as a local supplier of...

Why PVH’s bylaw change matters for shareholders PVH (PVH) has amended its bylaws, cutting the ownership threshold needed for shareholders to call a special meeting to 25% of outstanding common stock. This change increases the potential influence of shareholders. See our latest analysis for PVH. PVH’s share price is US$66.45, with a 7 day share price return of 3.83% after a softer 30 and 90 day patch and a 5 year total shareholder return decline of 33.65%. This suggests longer term momentum...

DRDGOLD Limited (JSE:DRD) was recently added to the FTSE All-World Index (USD), broadening its representation in a widely followed global benchmark. This index inclusion can be material for DRDGOLD because it often attracts incremental demand from index-tracking funds and benchmark-aware institutional investors. We will now explore how DRDGOLD’s entry into the FTSE All-World Index may reshape its investment narrative for existing and prospective shareholders. AI is about to change...

Sylvamo (SLVM) has drawn investor attention after a choppy stretch for the share price, with the stock showing a decline of about 13% over the past month and a decline of nearly 18% over the past three months. See our latest analysis for Sylvamo. At a share price of about $40.30, Sylvamo’s recent 7 day share price return of 3.95% contrasts with a 30 day share price return showing a 12.88% decline and a 1 year total shareholder return showing a 37.54% loss, which points to fading momentum as...

Kontoor Brands (KTB) is back in focus after Wrangler partnered with Dr. Scholl’s Shoes on a limited-edition capsule that blends Western themed footwear with a co-branded denim jacket aimed at festival season shoppers. See our latest analysis for Kontoor Brands. Despite the recent brand collaborations, Kontoor Brands’ 1-day share price return of 3.15% and 7-day share price return of 2.43% sit against a 90-day share price return of 7.03% and a 5-year total shareholder return of 64.50%. This...

Why TG Therapeutics’ new credit facility matters for shareholders TG Therapeutics (TGTX) shares are reacting to a fresh financing move after the company entered a new five year, US$750 million senior secured credit facility with funds managed by Blue Owl Capital. For you as a shareholder or potential investor, the key points are the repayment of the prior US$250 million facility, a net US$500 million in non dilutive capital, and access to as much as US$1 billion in total debt capacity at the...

The closure of the Strait of Hormuz and the resulting oil supply shock have pushed Exxon Mobil (XOM) into sharper focus for investors, as the stock trades near US$165 with strong recent returns. See our latest analysis for Exxon Mobil. The recent 1-day share price return of 1.33% and 7-day share price return of 4.60% add to a strong 30-day move of 10.83%. The 1-year total shareholder return of 45.15% and 5-year total shareholder return of 249.11% point to momentum that has built steadily...